면역관문억제제 내성 암 시장 보고서(2026년)

Checkpoint inhibitor refractory cancer refers to cancers that do not respond to immune checkpoint inhibitors such as PD-1, PD-L1, or CTLA-4 blockers. Resistance can be primary, where the cancer shows no initial response, or acquired, where the disease progresses after an initial benefit. Managing these cases often requires alternative approaches, including combination immunotherapies, targeted agents, or novel experimental strategies.

The main therapies for checkpoint inhibitor refractory cancer include immune checkpoint inhibitors, combination therapies, and targeted therapies. Immune checkpoint inhibitors are drugs that enable the immune system to detect and attack cancer cells by blocking proteins that suppress immune cell activity. These therapies are applied to various cancer types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, triple-negative breast cancer (TNBC), colorectal cancer, and others. Their mechanisms of action include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, and others, with routes of administration including intravenous (IV) and oral. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the checkpoint inhibitor refractory cancer market by increasing the cost of imported biologics, monoclonal antibodies, and specialized oncology drugs, affecting treatment affordability and availability. Hospital and retail pharmacies in regions such as North America and Europe, which rely heavily on imported oncology therapeutics, are most affected. These cost pressures have influenced pricing and reimbursement dynamics. However, tariffs have also encouraged domestic manufacturing, local biologics production, and innovation in alternative therapeutic approaches, supporting long-term market sustainability.

The checkpoint inhibitor refractory cancer market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitor refractory cancer market statistics, including checkpoint inhibitor refractory cancer industry global market size, regional shares, competitors with a checkpoint inhibitor refractory cancer market share, detailed checkpoint inhibitor refractory cancer market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitor refractory cancer industry. This checkpoint inhibitor refractory cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The checkpoint inhibitor refractory cancer market size has grown rapidly in recent years. It will grow from $36.69 billion in 2025 to $40.97 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing use of immune checkpoint inhibitors in oncology, rising incidence of advanced-stage cancers, limited treatment options after immunotherapy failure, growing oncology drug approvals, expansion of cancer treatment centers.

The checkpoint inhibitor refractory cancer market size is expected to see rapid growth in the next few years. It will grow to $63.02 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to development of next-generation immunotherapies, increasing investment in combination and targeted therapies, rising precision oncology adoption, expansion of global oncology clinical trials, growing focus on personalized cancer treatment strategies. Major trends in the forecast period include rising focus on overcoming primary and acquired resistance to checkpoint inhibitors, increasing adoption of combination immunotherapy regimens, growth in targeted therapies for immunotherapy-refractory cancers, expansion of clinical trials for novel and experimental therapies, rising demand for biomarker-based patient stratification.

The rising incidence of cancer is expected to drive the growth of the checkpoint inhibitor refractory cancer market in the coming years. Cancer is characterized by the uncontrolled division and growth of abnormal cells in the body. The increasing incidence of cancer is largely attributed to an aging population, as longer life expectancy raises the likelihood of developing cancer over time. Identifying checkpoint inhibitor refractory cancer is critical in oncology management, as it allows early recognition of treatment resistance, enabling clinicians to modify therapies promptly and explore alternative approaches to improve patient outcomes. For instance, in February 2025, according to the United Nations, a US-based intergovernmental organization, approximately 2.3 million new breast cancer cases were diagnosed globally in 2022, resulting in 670,000 deaths. Projections indicate a 38% increase in cases and a 68% rise in annual deaths by 2050. Therefore, the rising incidence of cancer is propelling the growth of the checkpoint inhibitor refractory cancer market.

Major companies in the checkpoint inhibitor refractory cancer market are focusing on developing innovative therapies such as dual selective inhibitors to reduce the risk of drug resistance by simultaneously targeting two key pathways involved in disease progression. Dual selective inhibitors are compounds designed to block two distinct biological targets or pathways at the same time while minimizing effects on unrelated pathways. For example, in March 2025, Pliant Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, reported interim Phase 1 data for PLN-101095 in patients with immune checkpoint inhibitor-refractory advanced solid tumors. The data demonstrated promising early activity and a manageable safety profile. At the highest tested dose of 1,000 mg twice daily in combination with pembrolizumab, the trial showed a 50% objective response rate, including confirmed partial responses in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, with significant tumor reductions. PLN-101095 was generally well tolerated, with most treatment-emergent adverse events being mild to moderate. The study is ongoing, with higher-dose cohorts currently enrolling and additional data expected by the end of 2025.

In October 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, acquired Mirati Therapeutics Inc. for an undisclosed amount. This acquisition enables Bristol-Myers Squibb to strengthen and diversify its oncology portfolio by integrating Mirati's innovative therapies and clinical-stage assets, particularly for KRAS-mutated cancers and checkpoint inhibitor refractory cancers. Mirati Therapeutics Inc. is a US-based company specializing in therapies for checkpoint inhibitor refractory cancers.

Major companies operating in the checkpoint inhibitor refractory cancer market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., Pliant Therapeutics Inc.

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the checkpoint inhibitor refractory cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the checkpoint inhibitor refractory cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The checkpoint inhibitor refractory cancer market includes revenues earned by entities by providing services such as diagnostic and biomarker services, clinical trials and research services, specialized oncology treatment services, and patient support and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The checkpoint inhibitor refractory cancer market consists of sales of tumor-infiltrating lymphocyte (TIL) therapy kits, genomic sequencing panels, tumor organoids, drug discovery tools, and bispecific antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Checkpoint Inhibitor Refractory Cancer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses checkpoint inhibitor refractory cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for checkpoint inhibitor refractory cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The checkpoint inhibitor refractory cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy: Immune Checkpoint Inhibitors; Combination Therapies; Targeted Therapies
• 2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC); Melanoma; Renal Cell Carcinoma (RCC); Head And Neck Squamous Cell Carcinoma (HNSCC); Urothelial Carcinoma; Triple-Negative Breast Cancer (TNBC); Colorectal Cancer; Other Cancer Types
• 3) By Mechanism Of Action: Programmed Cell Death Protein (PD)-1 Inhibitors; Programmed Death-Ligand (PD)-L1 Inhibitors; Cytotoxic T-Lymphocyte-Associated Protein (CTLA)-4 Inhibitors; Other Mechanism Of Actions
• 4) By Administration Route: Intravenous (IV); Oral
• 5) By End-User: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Immune Checkpoint Inhibitors (ICIs): PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 2) By Combination Therapies: Checkpoint Inhibitor + Chemotherapy; Checkpoint Inhibitor + Targeted Therapy; Checkpoint Inhibitor + Other Immunotherapies; Dual Checkpoint Inhibitor Combinations
• 3) By Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies Targeting Specific Cancer Markers
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co. Inc.; AbbVie Inc.; Novartis International AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline Plc; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Eisai Co. Ltd.; Exelixis Inc.; Exicure Inc.; ImmunityBio Inc.; ENB Therapeutics Inc.; Kartos Therapeutics Inc.; Pliant Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Checkpoint Inhibitor Refractory Cancer Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Checkpoint Inhibitor Refractory Cancer Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Checkpoint Inhibitor Refractory Cancer Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Focus On Overcoming Primary And Acquired Resistance To Checkpoint Inhibitors
  • 4.2.2 Increasing Adoption Of Combination Immunotherapy Regimens
  • 4.2.3 Growth In Targeted Therapies For Immunotherapy-Refractory Cancers
  • 4.2.4 Expansion Of Clinical Trials For Novel And Experimental Therapies
  • 4.2.5 Rising Demand For Biomarker-Based Patient Stratification

5. Checkpoint Inhibitor Refractory Cancer Market Analysis Of End Use Industries

• 5.1 Hospital Pharmacies
• 5.2 Retail Pharmacies
• 5.3 Online Pharmacies
• 5.4 Specialty Oncology Centers
• 5.5 Cancer Research Institutes

6. Checkpoint Inhibitor Refractory Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Checkpoint Inhibitor Refractory Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Checkpoint Inhibitor Refractory Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Checkpoint Inhibitor Refractory Cancer Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Checkpoint Inhibitor Refractory Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Checkpoint Inhibitor Refractory Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Checkpoint Inhibitor Refractory Cancer Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Checkpoint Inhibitor Refractory Cancer Market Segmentation

• 9.1. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies
• 9.2. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head And Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types
• 9.3. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Programmed Cell Death Protein (PD)-1 Inhibitors, Programmed Death-Ligand (PD)-L1 Inhibitors, Cytotoxic T-Lymphocyte-Associated Protein (CTLA)-4 Inhibitors, Other Mechanism Of Actions
• 9.4. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous (IV), Oral
• 9.5. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.6. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
• 9.7. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Checkpoint Inhibitor + Chemotherapy, Checkpoint Inhibitor + Targeted Therapy, Checkpoint Inhibitor + Other Immunotherapies, Dual Checkpoint Inhibitor Combinations
• 9.8. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies Targeting Specific Cancer Markers

10. Checkpoint Inhibitor Refractory Cancer Market Regional And Country Analysis

• 10.1. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market

• 11.1. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Checkpoint Inhibitor Refractory Cancer Market

• 12.1. China Checkpoint Inhibitor Refractory Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Checkpoint Inhibitor Refractory Cancer Market

• 13.1. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Checkpoint Inhibitor Refractory Cancer Market

• 14.1. Japan Checkpoint Inhibitor Refractory Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Checkpoint Inhibitor Refractory Cancer Market

• 15.1. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Checkpoint Inhibitor Refractory Cancer Market

• 16.1. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Checkpoint Inhibitor Refractory Cancer Market

• 17.1. South Korea Checkpoint Inhibitor Refractory Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Checkpoint Inhibitor Refractory Cancer Market

• 18.1. Taiwan Checkpoint Inhibitor Refractory Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Checkpoint Inhibitor Refractory Cancer Market

• 19.1. South East Asia Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Checkpoint Inhibitor Refractory Cancer Market

• 20.1. Western Europe Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Checkpoint Inhibitor Refractory Cancer Market

• 21.1. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Checkpoint Inhibitor Refractory Cancer Market

• 22.1. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Checkpoint Inhibitor Refractory Cancer Market

• 23.1. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Checkpoint Inhibitor Refractory Cancer Market

• 24.1. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Checkpoint Inhibitor Refractory Cancer Market

• 25.1. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market

• 26.1. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Checkpoint Inhibitor Refractory Cancer Market

• 27.1. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Checkpoint Inhibitor Refractory Cancer Market

• 28.1. North America Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Checkpoint Inhibitor Refractory Cancer Market

• 29.1. USA Checkpoint Inhibitor Refractory Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Checkpoint Inhibitor Refractory Cancer Market

• 30.1. Canada Checkpoint Inhibitor Refractory Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Checkpoint Inhibitor Refractory Cancer Market

• 31.1. South America Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Checkpoint Inhibitor Refractory Cancer Market

• 32.1. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Checkpoint Inhibitor Refractory Cancer Market

• 33.1. Middle East Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Checkpoint Inhibitor Refractory Cancer Market

• 34.1. Africa Checkpoint Inhibitor Refractory Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Segmentation By Cancer Type, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Checkpoint Inhibitor Refractory Cancer Market Regulatory and Investment Landscape

36. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape And Company Profiles

• 36.1. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Checkpoint Inhibitor Refractory Cancer Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Checkpoint Inhibitor Refractory Cancer Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

37. Checkpoint Inhibitor Refractory Cancer Market Other Major And Innovative Companies

• Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., Pliant Therapeutics Inc.

38. Global Checkpoint Inhibitor Refractory Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Checkpoint Inhibitor Refractory Cancer Market

40. Checkpoint Inhibitor Refractory Cancer Market High Potential Countries, Segments and Strategies

• 40.1 Checkpoint Inhibitor Refractory Cancer Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Checkpoint Inhibitor Refractory Cancer Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Checkpoint Inhibitor Refractory Cancer Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer